Biotechnology Company Announces Preclinical Data: Type 2 NKT Activating Molecules
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE).
As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.